US FDA greenlights Viridian’s thyroid eye disease drug

Viridian thyroid eye disease drug approved (VRDN:NASDAQ)

Viridian Therapeutics (VRDN) stock is in focus as the company launches Lumvoa soon after the FDA approval of the thyroid eye disease therapy. Read more here.

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 26, 2026-

US FDA greenlights Viridian's thyroid eye disease drug

Viridian Therapeutics' Lumvoa receives FDA approval for thyroid eye disease across active and chronic stages

New IGF-1R antibody Lumvoa receives FDA nod for active and chronic thyroid eye disease, offering rapid proptosis relief and diplopia improvement.

FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza

The FDA approved Viridian Therapeutics' thyroid eye disease drug veligrotug, kicking off a competition with Amgen’s blockbuster Tepezza. Viridian’s drug, to be marketed as Lumvoa, will be priced “in line with” Tepezza, CEO Steve Mahoney ...